Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

158P - Prognosis of pregnancy after breast cancer diagnosis according to the treatment


16 Sep 2021


ePoster Display


Tumour Site

Breast Cancer


Sungmin Park


Annals of Oncology (2021) 32 (suppl_5): S407-S446. 10.1016/annonc/annonc687


S. Park1, S.Y. Bae2, J.S. Lee3

Author affiliations

  • 1 Department Of Breast Surgery, Chungbuk National University Hospital, 28644 - Cheongju/KR
  • 2 Department Of Surgery, The Catholic University of Korea Seoul St. Mary's Hospital, 06591 - Seoul/KR
  • 3 Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, 05505 - Seoul/KR

Abstract 158P


In this study, we evaluated the incidence and outcomes of pregnancy after the diagnosis of breast cancer. Additionally, we evaluated the prognosis of patients who became pregnant after breast cancer, according to the treatment.


This was a retrospective cohort study of women aged 20–45 years who were surgically treated for breast cancer between 2004 and 2014 using the Korean National Health Insurance database. Patients were classified according to the treatment: (1) patients who did not receive any treatment, (2) patients who received endocrine therapy-only, (3) chemotherapy-only, (4) endocrine therapy and chemotherapy, (5) chemotherapy and targeted therapy, and (6) endocrine therapy, chemotherapy, and targeted therapy.


Of the 49,348 patients aged 20 to 45 years and who had been newly diagnosed with breast cancer, 2,045 (4.1%) became pregnant after a breast cancer diagnosis. In survival analysis, the pregnant group had a better prognosis and reduced risk of death than the non-pregnant group (HR, 0.41; 95% CI, 0.33 to 0.51, p < 0.001). Among the pregnant group, the HR of the risk of death was 0.17 (95% CI, 0.07 to 0.41, p < 0.001) for patients who became pregnant ≥ 49 months after the diagnosis. In the endocrine therapy-only and the chemotherapy-only groups, pregnant group had a significantly lower risk of death than those in the non-pregnant group (HR, 0.34; 95% CI, 0.12 to 0.98, p = 0.045; HR, 0.29; 95% CI, 0.21 to 0.4, p < 0.001). In patients who received endocrine therapy and chemotherapy, the pregnant group had a better prognosis than the non-pregnant group (HR, 0.57; 95% CI, 0.41 to 0.79, p < 0.001). There was no significant difference between the pregnant group and the non-pregnant group in patients who received chemotherapy and targeted therapy with or without endocrine therapy.


The risk of death was low in women who became pregnant ≥ 49 months after the diagnosis of breast cancer. The prognosis of the pregnant group was better than that of the non-pregnant group, regardless of endocrine therapy. The prognosis of pregnant women was non-inferior to that of non-pregnant women, even in women who received targeted therapy. These findings provide reassurance to patients with HER2-positive cancer who are considering future pregnancy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Korean Breast Cancer Society.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.